UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~December~~February ~~2025~~2026

Commission File Number: 001-42450

Zhengye Biotechnology Holding Limited

No. 1 Lianmeng Road, Jilin Economic & Technical Development Zone Jilin City, Jilin Province, China

~~Jilin City, Jilin Province, China~~ (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

~~Explanatory~~Resignation ~~Note~~of Independent Director

~~Zhengye~~On ~~Biotechnology~~February ~~Holding~~18, ~~Limited~~2026, aMr. ~~Cayman~~Wenbin Wang, an independent ~~Islands~~director ~~exempted~~of ~~company~~Zhengye Biotechnology Holding Limited (the “Company”), isresigned ~~furnishing~~from ~~its~~the ~~unaudited~~board ~~financial~~of ~~statements~~directors (the “Board”) and ~~notes~~each ~~for~~of the ~~six~~Audit ~~months~~Committee, ~~ended June~~the 30Compensation Committee, ~~2025.~~and ~~The~~the ~~financial~~Nominating ~~statements~~ and ~~notes~~Corporate ~~are~~Governance ~~attached~~Committee, and as ~~Exhibit~~the ~~99.1~~chairperson of tothe ~~this~~Compensation ~~report~~Committee of the Board, effective February 18, 2026. ~~Management~~Mr. Wang’s ~~Discussion~~resignation from the Board and ~~Analysis~~the three committees ofwas ~~Financial~~due ~~Condition~~to personal reasons and ~~Results~~not a result of ~~Operations~~any ~~for~~disagreement with the ~~six~~Company ~~months~~on ~~ended~~any ~~June~~matter 30related to the operations, ~~2025~~policies, isor practices ~~attached~~of asthe ~~Exhibit~~Company. 99Mr.2 Wang acknowledges that he has been paid all amounts due to ~~this~~him ~~report~~and is not entitled to any payments or benefits of any kind from the Company, and irrevocably and unconditionally releases the Company of and from all claims, demands, actions, and causes of actions.

~~Exhibit~~The ~~Index~~Company acknowledges that the board vacancy created by the resignation of Mr. Wenbin Wang caused the Company to fall out of compliance with Nasdaq Listing Rule 5605(b)(1), which requires that a majority of the board of directors of a Nasdaq-listed company be comprised of independent directors. The Company intends to cure this deficiency by seeking shareholder approval to appoint a new independent director at its annual general meeting to be held in March 2026.

Exhibit No.		Description
99.1		Unaudited Consolidated Financial Statements and Notes of Zhengye Biotechnology Holding Limited for the Six Months Ended June 30, 2025 and 2024
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations
101. INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Zhengye Biotechnology Holding Limited
Date: December 12, 2025	By:	/s/ Songlin Song
Date: February 23, 2026	By:	/s/ Songlin Song
	Name:	Songlin Song
	Title:	Chief Executive Officer

Filing Compare · Zhengye Biotechnology Holding Ltd